<DOC>
	<DOC>NCT00396916</DOC>
	<brief_summary>The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated</brief_summary>
	<brief_title>Hybrid PET/CT in Cancer Patients</brief_title>
	<detailed_description />
	<criteria>Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test. Patients with newly diagnosed metastatic cancer with unknown primary tumor Glucose levels below 150200 Patient signed informed consent Pregnant or lactating women Patient unable or not willing to tolerate the test until its completion One or more of the inclusion criteria is not fulfilled</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>cancer patients</keyword>
</DOC>